公开(公告)号：US5871487A

公开(公告)日：1999-02-16

申请号：US814594

申请日：1997-03-10

Applicant: Nicholas Warner ,  Moses Goddard ,  John Mills

Inventor： Nicholas Warner ,  Moses Goddard ,  John Mills

IPC: A61B19/00 ,  A61B17/56

CPC classification number: A61B90/11

Abstract: A microdrive apparatus useful in human stereotactic surgery is disclosed. Such apparatus permits safe and accurate placement of a surgical instrument, such as a cannula, into a portion of the central nervous system, e.g. the brain and spinal cord, of a patient by simple mechanical operation.

Abstract translation: 公开了一种在人体立体定向手术中有用的微驱动装置。 这样的装置允许将外科器械（例如插管）安全和准确地放置到中枢神经系统的一部分中，例如， 大脑和脊髓，通过简单的机械操作。

公开(公告)号：US5643286A

公开(公告)日：1997-07-01

申请号：US265242

申请日：1994-06-24

Applicant: Nicholas Warner ,  Moses Goddard ,  John Mills

Inventor： Nicholas Warner ,  Moses Goddard ,  John Mills

IPC: A61B19/00 ,  A61B17/56

CPC classification number: A61B90/11

Abstract: The present invention is directed to microdrive apparatus useful in human stereotactic surgery. Such apparatus permits safe and accurate placement of a surgical instrument, such as a cannula, into a portion of the central nervous system, e.g. the brain and spinal cord, of a patient by simple mechanical operation.

Abstract translation: 本发明涉及用于人体立体定向手术的微驱动装置。 这样的装置允许将外科器械（例如插管）安全和准确地放置到中枢神经系统的一部分中，例如， 大脑和脊髓，通过简单的机械操作。

公开(公告)号：US5554148A

公开(公告)日：1996-09-10

申请号：US453571

申请日：1995-05-26

Applicant: Patrick Aebischer ,  Paul C. DiCesare ,  Moses Goddard ,  Paul J. Mulhauser

Inventor： Patrick Aebischer ,  Paul C. DiCesare ,  Moses Goddard ,  Paul J. Mulhauser

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/22 ,  A61K35/12 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/12 ,  A61K35/30 ,  A61K38/1825 ,  A61K9/0024 ,  A61K9/0085 ,  A61M31/002 ,  B01J13/02 ,  C12N11/04 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  A61K2035/126 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Refillable immunoisolatory neurological therapy devices for local and controlled delivery of a biologically active factor to the brain of a patient. The devices include a cell chamber adapted for infusion with nsecretory cells and having at least one semipermeable or permselective surface across which biologically active factors secreted by the cells can be delivered to the brain. The devices also include means for introducing secretory cells into the cell chamber, and means for renewing the cells or cell medium.

Abstract translation: 用于局部和控制地将生物活性因子递送到患者脑部的可补充的免疫隔离神经治疗装置。 所述装置包括适于与分泌细胞一起输注并具有至少一个半透性或选择性选择性表面的细胞室，细胞分泌的生物活性因子可以被输送到脑。 所述装置还包括用于将分泌细胞引入细胞室的装置和用于更新细胞或细胞培养基的装置。

公开(公告)号：US06179826B2

公开(公告)日：2001-01-30

申请号：US08741228

申请日：1996-10-29

Applicant: Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

Inventor： Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

IPC: A61M3100

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K9/0024 ,  A61K9/0085 ,  A61K35/55 ,  A61K2035/126 ,  A61M31/002 ,  A61M37/0069 ,  A61M39/0208 ,  A61M2210/0687 ,  A61M2210/0693 ,  B01J13/02 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  C12N11/04 ,  C12N2533/30 ,  A61M2230/005

Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a dibilatating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the proximal tip of the cannula (20b). Once the vehicle (40) is positioned near the proximal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).

Abstract translation: 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有二体化病症的受试者的脑，脊髓和其他靶区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的近端处。 一旦车辆（40）定位在套管（20）的近端附近，则套管从通道中移开，随后是推动器，使车辆（40）位于治疗部位（12）处。

公开(公告)号：US5487739A

公开(公告)日：1996-01-30

申请号：US459815

申请日：1995-06-02

Applicant: Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

Inventor： Patrick Aebischer ,  Moses Goddard ,  John G. Moldauer ,  Paul J. Mulhauser ,  Anne M. Rathbun ,  Paul R. Sanberg ,  Alfred V. Vasconcellos ,  Nicholas F. Warner

IPC: A61F2/02 ,  A61K9/00 ,  A61K9/50 ,  A61K35/12 ,  A61K35/55 ,  A61M31/00 ,  A61M39/02 ,  B01J13/02 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  A61K9/22

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61K35/55 ,  A61K9/0024 ,  A61K9/0085 ,  A61M31/002 ,  A61M37/0069 ,  A61M39/0208 ,  B01J13/02 ,  C12N11/04 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  A61K2035/126 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Implantable therapy systems are disclosed for the local and controlled delivery of a biologically active factor to the brain, spinal cord and other target regions of a subject suffering from a debilitating condition. The method of the invention involves surgically exposing an insertion site, generally located above a predetermined treatment site (12), in a patient. A cannula (20), having an obturator (30) or dilator (104) positioned therein, is inserted at the insertion site, defining a pathway to the treatment site. In some instances, the cannula can be inserted along the path of a guidewire (102) previously positioned at the treatment site. The cannula (20) is preferably a low friction polymeric material such as polytetrafluoroethylene. The cannula (20) generally has an open proximal end for receiving the obturator (30) or dilator (104), and an open distal end, preferably a tapered end, for delivery of neurologically active factors to the treatment site (12). The obturator (30) is then removed from the cannula (20), and a biocompatible tethered vehicle (40) containing a biologically active material is inserted into the cannula along the passageway. A pusher can be inserted within the cannula, behind the vehicle (40), to position the proximal end of the vehicle at the distal end of the cannula (20b). Once the vehicle (40) is positioned near the distal end of the cannula (20), the cannula is removed from the passageway, followed by the pusher, leaving the vehicle (40) positioned at the treatment site (12).

Abstract translation: 公开了植入式治疗系统，用于将局部和受控制的生物活性因子递送至患有衰弱病症的受试者的脑，脊髓和其他目标区域。 本发明的方法涉及通常在患者体内暴露通常位于预定治疗部位（12）上方的插入部位。 具有定位在其中的闭塞器（30）或扩张器（104）的插管（20）插入插入位置，从而限定到治疗部位的通路。 在一些情况下，套管可以沿着预先位于治疗部位的导丝（102）的路径插入。 插管（20）优选为低摩擦聚合材料，例如聚四氟乙烯。 插管（20）通常具有用于接收封闭器（30）或扩张器（104）的开放近端，以及用于将神经活性因子递送至治疗部位（12）的开口远端，优选地为锥形末端。 然后将塞子（30）从插管（20）中取出，并且将包含生物活性物质的生物相容性系留载体（40）沿通道插入插管中。 推动器可以插入插管内，在车辆（40）后面，以将车辆的近端定位在套管（20b）的远端。 一旦车辆（40）定位在套管（20）的远端附近，则套管从通道中移除，随后是推动器，使车辆（40）位于治疗部位（12）处。

公开(公告)号：US20070071734A1

公开(公告)日：2007-03-29

申请号：US11543015

申请日：2006-10-03

Applicant: Weng Tao ,  David Rein ,  Brenda Dean ,  Paul Stabila ,  Moses Goddard

Inventor： Weng Tao ,  David Rein ,  Brenda Dean ,  Paul Stabila ,  Moses Goddard

IPC: A61K48/00 ,  A61F2/02

CPC classification number: A61K48/0008

Abstract: ARPE-19 cells were evaluated as a platform cell line for encapsulated and unencapsulated cell-based delivery technology. ARPE-19 cells were found to be hardy (the cell line is viable under stringent conditions, such as in central nervous system or intra-ocular environment); can be genetically modified to secrete the protein of choice; have a long life span; are of human origin; have good in vivo device viability; deliver efficacious quantity of growth factor; trigger no or low level host immune reaction, and are non-tumorigenic.

Abstract translation: 评估ARPE-19细胞作为用于封装和未包封的基于细胞的递送技术的平台细胞系。 发现ARPE-19细胞是强力的（细胞系在严格条件下存活，例如在中枢神经系统或眼内环境中）; 可以进行遗传修饰以分泌选择的蛋白质; 寿命长 是人类的; 具有良好的体内器官生存能力; 提供有效数量的生长因子; 触发无或低水平的宿主免疫反应，并且是非致瘤性的。